Skip to content
Procter & Gamble Health logo

Procter & Gamble Health

PGHL NSE
₹5,738.00 −121.00 (−2.07%)
P/E
26.69
View as Markdown
MCP
Close 4 Nov 2026 ₹5,738.00 −258.50 −4.31% 1Y
Start ₹5,996.50

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
83.90%
Debt to Equity
0.02
EPS (TTM)
₹214.99
Book Value
₹316.01
Market Cap
—
P/E (TTM)
26.69
P/B
18.16
ROE
61.90%
Dividend Yield
3.50%
EBITDA
₹474 Cr
52W High
₹6,975.00
52W Low
₹4,707.00
Day Range
₹5,655.00 – ₹5,999.00
Volume
9,415

Peer Comparison

Healthcare › Pharmaceuticals

Procter & Gamble Health peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Procter & Gamble Health (this company)
₹5,738.0026.69₹9,643 Cr18.163.50%61.90%83.90%₹1,433 Cr₹358 Cr
Median 8 companies₹2,048.6037.20₹1,25,337 Cr7.290.70%17.40%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

60 Good

Data confidence 100/100

Category scores

Quality
70
Strong
Returns, margins, earnings quality 22% weight
Valuation
68
Strong
Cheap vs sector & own history 24% weight
Growth
41
Weak
Sales & profit trajectory 9% weight
Financial Health
84
Strong
Solvency, leverage, coverage 9% weight
Momentum
38
Weak
Trend strength, vol-adjusted 12% weight
Ownership
56
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

4
  • Company is almost debt free.
  • Stock is providing a good dividend yield of 3.06%.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 42.6%
  • Company has been maintaining a healthy dividend payout of 87.1%

Weaknesses

2
  • Stock is trading at 16.0 times its book value
  • The company has delivered a poor sales growth of 0.76% over past five years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish3412
OscillatorsBullish243
Moving AveragesStrong Bullish109

Key readings

RSI (14)
61.74
Neutral
MACD (12,26,9)
76.20
Bullish
SMA (50)
5,464.68
Bullish
SMA (200)
5,581.33
Bullish

As of

Analyst Rating

Based on 1 analysts
BUY100%

1 of 1 analyst rates Buy, 0 Hold, 0 Sell.

As of

BUY
1
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10YIrregular period
5YIrregular period
3YIrregular period
1YIrregular period
TTM+12.57%

Net profit

Net profit growth by window
10YIrregular period
5YIrregular period
3YIrregular period
1YIrregular period
TTM+19.33%

Operating cash flow

Operating cash flow growth by window
10YIrregular period
5YIrregular period
3YIrregular period
1YIrregular period
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10YIrregular period
5YIrregular period
3YIrregular period
1YIrregular period
TTM+0.47 pp

Revenue by year

Revenue by year, ₹ crore
Dec 2015₹940 Cr
Dec 2016₹993 Cr
Dec 2017₹698 Cr
Dec 2018₹849 Cr
Dec 2019₹927 Cr
Jun 2021₹1,009 Cr
Jun 2022₹1,114 Cr
Jun 2023₹1,230 Cr
Jun 2024₹1,151 Cr
Mar 2026₹1,408 Cr

Net profit by year

Net profit by year, ₹ crore
Dec 2015₹54.00 Cr
Dec 2016₹79.00 Cr
Dec 2017₹94.00 Cr
Dec 2018₹839 Cr
Dec 2019₹159 Cr
Jun 2021₹177 Cr
Jun 2022₹193 Cr
Jun 2023₹229 Cr
Jun 2024₹201 Cr
Mar 2026₹327 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹485 Cr +2.4% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk medium

Procter & Gamble Health Ltd is a nearly debt-free healthcare company with a market cap of ₹10,447 Cr, trading at a PE of 32.3x and 20.1x book value. The company delivers exceptional return on equity (62% last year, 43% 3-year average) and maintains a dividend payout of 123%, but has historically struggled with revenue growth at just 0.76% CAGR over five years despite a recent TTM sales surge of 51%.

Bull Case 8
  • Virtually debt-free balance sheet provides financial resilience and flexibility for future investments
  • Exceptional ROE of 62% in the last year, with a 3-year average of 43% and 10-year average of 31%, indicating highly efficient capital deployment
  • Dividend payout ratio of 123% signals strong cash generation and shareholder-friendly capital allocation, with a current yield of 2.52%
  • TTM sales growth of 51% represents a significant acceleration from the 5-year CAGR of just 1%, suggesting a potential inflection point in revenue trajectory
  • TTM profit growth of 39% demonstrates operating leverage and margin expansion alongside the revenue surge
  • 3-year compounded profit growth of 19% materially outpaces 3-year sales growth of 8%, reflecting improving profitability and cost discipline
  • 10-year stock CAGR of 25% shows long-term wealth creation track record for patient investors
  • Backed by the global Procter & Gamble parentage, providing access to R&D, established brands, and operational best practices in healthcare
Bear Case 7
  • 5-year compounded sales growth of only 0.76% indicates structural challenges in scaling revenue over extended periods
  • PE ratio of 32.3x is elevated for a company with a 5-year profit CAGR of just 5%, implying the market prices in growth not yet consistently delivered
  • 5-year stock CAGR of only 2% suggests prolonged periods of stagnant shareholder returns despite the high ROE
  • 10-year compounded sales growth of just 4% underscores limited top-line expansion in what should be a growing healthcare market
  • Dividend payout exceeding 100% at 123% means the company is returning more than it earns, which may not be sustainable long-term or limits reinvestment capacity
  • The sharp TTM sales jump of 51% may reflect one-time factors or base effects rather than sustainable organic growth, given the weak long-term track record
  • 1-year stock CAGR of 10% and 3-year CAGR of 7% lag broader market indices, indicating relative underperformance in recent periods

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

121d ago

TL;DR: P&G Health is executing well with clear productivity targets (INR 35cr savings) and rewarding shareholders with a healthy Rs 45 dividend. No material headwinds are visible in recent news flow. The VMS category growing at 9% CAGR provides a strong secular tailwind. The management reshuffle bears watching but the overall trend remains stable to positive.

Positives 2
  • Rs 45 dividend declared FY26 Jun 26

    P&G Health recommended a final dividend of Rs 45 per share for FY 2025-26, with tax document submission deadline of August 12, 2026.

  • INR 35cr productivity savings planned Jun 18

    P&G Health outlined its Q1FY26 strategy highlighting INR 35 crores in productivity savings and a 9% CAGR in the VMS (Vitamins, Minerals & Supplements) category.

Neutral 1
  • Senior management reshuffle from July Jun 25

    Key senior management changes effective July 1, 2026, including the appointment of Shine Matthew Sunny to a leadership role.

Quarterly Results

₹ Cr
PGHL quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
301
305
310
252
284
313
310
311
339
325
374
370
364
382
Expenses
256
216
208
185
236
199
186
230
248
205
263
235
264
230
Operating Profit
45
89
102
67
48
114
123
81
90
120
110
136
100
152
OPM %
15%
29%
33%
27%
17%
36%
40%
26%
27%
37%
30%
37%
27%
40%
Other Income
5
6
5
2
−18
3
4
3
4
5
4
4
36
4
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
6
6
7
7
7
6
6
5
5
6
6
6
6
6
PBT
44
88
100
63
23
111
122
79
89
119
109
133
129
150
Tax %
32%
26%
28%
26%
26%
26%
25%
22%
25%
26%
29%
29%
26%
26%
Net Profit
30
66
72
47
17
82
91
61
66
89
78
95
96
112
EPS (₹)
17.96
39.5
43.42
28.05
10.11
49.6
54.76
36.86
39.87
53.34
46.74
56.99
57.92
—

Sep 2026: from the results filed on 2 Nov 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
PGHL profit and loss, annual, ₹ crore
Particulars Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020 18mJun 2021Jun 2022Jun 2023Jun 2024Mar 2025 9mMar 2026TTM
Sales
940
993
698
849
927
1,356
1,009
1,114
1,230
1,151
934
1,408
1,433
Expenses
855
877
621
701
723
1,037
762
846
905
845
616
949
967
Operating Profit
85
116
77
148
204
319
246
268
325
307
319
459
466
OPM %
9%
12%
11%
17%
22%
24%
24%
24%
26%
27%
34%
33%
33%
Other Income
22
24
74
768
48
66
18
13
18
−5
10
15
49
Interest
0
0
0
0
0
0
1
0
1
1
0
1
1
Depreciation
23
25
19
21
17
29
30
27.81
28
27
17
24
24
PBT
83
115
132
895
234
355
233
253
314
273
312
450
490
Tax %
36%
31%
29%
6%
32%
28%
24%
24%
27%
26%
25%
27%
—
Net Profit
54
79
94
839
159
254
177
193
229
201
234
327
357
EPS (₹)
32.27
47.67
56.57
505
95.64
153
107
116
138
121
141
197
215
Div. Payout %
23%
23%
27%
87%
0%
150%
122%
45%
69%
215%
89%
104%
—

Balance Sheet

₹ Cr
PGHL balance sheet, annual, ₹ crore
Particulars Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025Mar 2026
Equity Capital
17
17
17
17
17
17
17
17
17
17
17
17
Reserves
575
647
717
1,524
800
890
687
600
734
522
520
508
Borrowings
0
0
0
0
0
0
8
3
12
10
8
9
Other Liabilities
192
215
258
219
250
269
275
269
338
247
250
308
Total Liabilities
784
879
991
1,759
1,067
1,176
986
888
1,101
794
794
841
Fixed Assets
132
111
115
104
101
101
104
112
144
128
116
102
CWIP
7
30
9
17
11
21
39
41
32
6
11
14
Investments
42
28
70
0
0
0
0
0
0
0
0
0
Other Assets
603
711
797
1,639
954
1,053
843
736
925
660
667
726
Total Assets
784
879
991
1,759
1,067
1,176
986
888
1,101
794
794
841

Cash Flow

₹ Cr
PGHL cash flow, annual, ₹ crore
Particulars Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025Mar 2026
Operating
83
107
54
−130
—
235
247
170
236
228
169
338
Investing
−68
−75
−48
1,270
—
165
−32
−26
−22
−7
10
1
Financing
−12
−15
−22
−30
—
−883
−387
−289
−98
−418
−235
−344
Net Cash Flow
4
17
−16
1,109
—
−483
−172
−145
116
−197
−56
−5
Free Cash Flow
38
75
24
−157
—
212
196
132
198
207
168
323
CFO/EBITDA
136
138
147
117
—
106
128
87
100
102
78
96

Ratios

PGHL financial ratios, annual
Particulars Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Mar 2025Mar 2026
Debtor Days
49
39
64
28
30
26
22
27
34
27
57
43
Inventory Days
140
145
243
154
139
113
138
124
136
120
152
137
Days Payable
55
67
128
124
106
105
209
185
239
184
239
192
Cash Conversion Cycle
134
118
179
58
63
34
−49
−34
−69
−37
−30
−13
Working Capital Days
69
52
94
42
22
23
7
17
15
19
48
30
ROCE %
15%
18%
16%
78%
20%
29%
29%
38%
45%
45%
48%
84%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Procter & Gamble Health insights

64 extracted metrics across FY12–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 51.82%
  • Public 23.35%
  • DIIs 12.63%
  • FIIs 6.42%
  • Others 5.78%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Procter & Gamble Health

What does Procter & Gamble Health Ltd do?
P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.
Where is Procter & Gamble Health Ltd (PGHL) listed?
Procter & Gamble Health Ltd trades as PGHL on the NSE and under code 500126 on the BSE.
Which sector does Procter & Gamble Health Ltd belong to?
Procter & Gamble Health Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd trades at a PE ratio of 26.69 as of 4 Nov 2026, on earnings per share of ₹214.99, against a book value of ₹316.01 per share.
What is the 52-week high and low of Procter & Gamble Health Ltd?
Over the last 52 weeks Procter & Gamble Health Ltd has traded between ₹4,707 and ₹6,975 as of 4 Nov 2026.
Does Procter & Gamble Health Ltd pay dividends?
Procter & Gamble Health Ltd has a dividend yield of 3.50%.
What is the Return on Equity (ROE) of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd reported a return on equity of 61.90%. Its debt-to-equity ratio is 0.02.

Company Information

P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.

Website pghealthindia.com
CEO Mr. Milind Vasant Thatte M.B.A.
Employees 1,326
Listed 24 Apr 1996
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/PGHL.md for Procter & Gamble Health Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month